Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2444
http://purl.obolibrary.org/obo/NCIT_C2444
|
|---|---|
| Preferred Name | Iodine I 131 Tositumomab |
| Definitions |
A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity. |
|---|---|
| prefLabel | Iodine I 131 Tositumomab
|
| label | Iodine I 131 Tositumomab
|
| PDQ_Closed_Trial_Search_ID | 42806
|
| code | C2444
|
| Has_Target | |
| prefixIRI | NCIT:C2444
|
| in_subset |
See more
See less
|
| Display_Name | Iodine I 131 Tositumomab
|
| Preferred_Name | Iodine I 131 Tositumomab
|
| FDA_UNII_Code | K1KT5M40JC
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Iodine I 131 Tositumomab
|
| CAS_Registry | 192391-48-3
|
| NSC Number | 715813
|
| NCI_Drug_Dictionary_ID | 42806
|
| Legacy Concept Name | I_131_Monoclonal_Antibody_Anti-B1
|
| type | |
| ALT_DEFINITION | A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42806
|
| Accepted_Therapeutic_Use_For | CD-20-antigen-expressing, relapsed or refractory, low-grade, follicular, or transformed Non-Hodgkins lymphoma
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0768182
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |